title: [Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines].
abstract: BACKGROUND
  Epidermal growth factor inhibitors (EGFR) are new antineoplastic agents that are increasingly being developed. They are basically used as second line treatment in advanced stage tumors. Appearance of a facial acneiform rash in patients treated with these drugs is common and characteristic. The literature proposes multiple topical and systemic treatment options. Up to now, there is no clear evidence on any of them.
  
  
  METHODS
  A descriptive study of 6 patients who were treated with 100 mg daily dose of doxycycline for 3 weeks was conducted. Clinical characteristics of the patients and treatment efficacy were analyzed.
  
  
  RESULTS
  Five of the six patients achieved total resolution of the acneiform rash with this treatment. One patient achieved partial response. After long follow-up periods and in spite of following treatment with the EGFR inhibitors, no relapse was observed.
  
  
  CONCLUSIONS
  Doxycycline is suggested as an effective treatment in this disease. Even though it is a short series, the results in our patients support this efficacy.
authors.affiliation: Servicio de Dermatología, Hospital Ramón y Cajal, Madrid, España. montsefdez@msn.com
authors.forename: Montse
authors.initials: M
authors.lastname: Fernández-Guarino
authors.forename: Bibiana
authors.initials: B
authors.lastname: Pérez García
authors.forename: Isabel
authors.initials: I
authors.lastname: Aldanondo Fernández de la Mora
authors.forename: Cristina
authors.initials: C
authors.lastname: García-Millán
authors.forename: Pilar
authors.initials: P
authors.lastname: Garrido López
authors.forename: Pedro
authors.initials: P
authors.lastname: Jaén Olasolo
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004318:Doxycycline / Q000008:administration & dosage*; D003875:Drug Eruptions / Q000188:drug therapy* / Q000209:etiology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005260:Female; D005500:Follow-Up Studies; D000077156:Gefitinib; D006801:Humans; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D004318:Doxycycline; D000077156:Gefitinib